| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
VIMIAN Stock Overview
Vimian Group AB (publ) engages in the animal health business worldwide.
Vimian Group AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr42.80 |
| 52 Week High | kr123.40 |
| 52 Week Low | kr37.26 |
| Beta | 0 |
| 1 Month Change | 2.44% |
| 3 Month Change | -21.68% |
| 1 Year Change | -58.45% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -47.10% |
Recent News & Updates
We Like These Underlying Return On Capital Trends At Vimian Group (STO:VIMIAN)
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Is Vimian Group AB (publ) (STO:VIMIAN) Trading At A 34% Discount?
Does the May share price for Vimian Group AB (publ) ( STO:VIMIAN ) reflect what it's really worth? Today, we will...
Shareholder Returns
| VIMIAN | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 2.0% | 2.7% | 2.3% |
| 1Y | -58.4% | -44.8% | -21.8% |
Return vs Industry: VIMIAN underperformed the Swedish Medical Equipment industry which returned -44.8% over the past year.
Return vs Market: VIMIAN underperformed the Swedish Market which returned -21.8% over the past year.
Price Volatility
| VIMIAN volatility | |
|---|---|
| VIMIAN Average Weekly Movement | 8.8% |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in SE Market | 12.6% |
| 10% least volatile stocks in SE Market | 4.5% |
Stable Share Price: VIMIAN is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: VIMIAN's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 700 | Fredrik Ullman | https://vimian.com |
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.
Vimian Group AB (publ) Fundamentals Summary
| VIMIAN fundamental statistics | |
|---|---|
| Market Cap | €1.56b |
| Earnings (TTM) | €4.10m |
| Revenue (TTM) | €197.57m |
387.3x
P/E Ratio8.0x
P/S RatioIs VIMIAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIMIAN income statement (TTM) | |
|---|---|
| Revenue | €197.57m |
| Cost of Revenue | €59.14m |
| Gross Profit | €138.43m |
| Other Expenses | €134.33m |
| Earnings | €4.10m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Nov 16, 2022
| Earnings per share (EPS) | 0.011 |
| Gross Margin | 70.07% |
| Net Profit Margin | 2.07% |
| Debt/Equity Ratio | 79.3% |
How did VIMIAN perform over the long term?
See historical performance and comparison